Good day. Thank you for standing by. Welcome to Tandem Diabetes Care first quarter 2023 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star one one on your telephone. You will hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Susan Morrison, Executive Vice President, Chief Administrative Officer. Please go ahead. Hello, everyone, welcome to Tandem's first quarter earnings call for 2023. We'd like to remind everyone that today's discussion will include forward-looking statements. These statements reflect management's expectations about future events, product development timelines, and financial performance and operating plans and speak only as of today's date. There are risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in our forward-looking statements. A list of factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is highlighted in our press release issued earlier today and under the Risk Factors portion and elsewhere in our most recent annual report on Form 10-K, quarterly report on Form 10-Q, and in our other SEC filings. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or other factors. Today's discussion will also include references to a number of GAAP and non-GAAP financial measures. Non-GAAP financial measures are provided to give our investors information that we believe is indicative of our core operating performance and reflects our ongoing business operations. We believe these non-GAAP financial measures facilitate better comparisons of operating results across reporting periods. Any non-GAAP information presented should not be considered as a substitution, independently or superior, to results prepared in accordance with GAAP. Please refer to our earnings release, quarterly report on Form 10-Q, and the investor center portion of our website for a reconciliation of these measures to their most directly comparable GAAP financial measure. Today's call participants include John Sheridan, our President and CEO; Brian Hansen, our Executive Vice President and Chief Commercial Officer; and Leigh Vosseller, our Executive Vice President and Chief Financial Officer. Following their prepared remarks, we'll open up the call for questions. Thank you in advance for limiting yourself to one question before getting back into the queue. John, you're welcome to begin. Thanks, Susan, and thank you everyone for joining us on today's call. We're coming out of the first quarter with confidence about our ability to achieve our key operational and commercial goals we set for this year. We continue to expand the insulin pump market while capturing competitive share and growing the number of Tandem customers purchasing a t:slim once again. This is a meaningful achievement in a highly competitive environment and a testament to our talented employees and our number one rated t:slim X2 with Control-IQ Technology. Internally, our teams continue to prepare for the launch of multiple new products in 2023. I'll talk more about each of these later in my comments, but overall, there's an enthusiasm at Tandem as we approach being able to offer another wave of innovative products to the diabetes community. With these launches, we'll be building upon our reputation for offering high-quality products and services that reduce the burden for diabetes management. We set our high bar with our easy-to-use t:slim X2 with Control-IQ technology. It continues to deliver outstanding clinical and quality of life improvements across a wide range of ages and demographics of people living with type 1 diabetes. This was recently highlighted in multiple publications, including the New England Journal of Medicine and Diabetes Technology & Therapeutics. The amount of positive data we are amassing for our market-leading AID capabilities is unrivaled. The New England Journal publication was the third time our t:slim was featured in the journal, this time focusing on the benefits of our Control-IQ technology for very young children. Diabetes Technology & Therapeutics recently published a meta-analysis of three randomized Control-IQ trials that demonstrated the immediate and sustained clinical benefit of our system. What this meta-analysis shows is that regardless of age, people with the highest baseline hemoglobin A1c and the lowest time in range experienced the greatest benefit, which is important as we work to bring the benefits of our technology to more people living with diabetes. Our technology is not only making a positive clinical impact, but we are also making a positive impact on the environment. By choosing a t:slim pump, our customers have kept more than 20 million batteries out of landfills since 2012. This is an important part of our longer-term product strategy as we look forward to similar environmental benefits from our future product offerings. It's this kind of performance and impact, combined with the customer experience our teams provide, that sets Tandem apart and allows us to continue growing our installed base three years following the launch of Control-IQ. I'd now like to ask Brian and Leigh to spend a few minutes talking about our performance in the first quarter, the broader commercial environment, and our expectations for the remainder of the year. Brian? Thanks, John. In my role, I get to spend quite a bit of time with healthcare providers and their patients, and the personal stories they share quickly put into perspective why our t:slim X2 insulin pump is rated number one. It's number one in terms of overall satisfaction, number one in terms of clinical outcomes, number one in ease of use, and number one in reducing burden. There is also a broad acknowledgement that Control-IQ technology continues to be best in class. Our automated correction bolus feature, customized profiles, superior overnight control, and ability to disconnect continue to be strong selling features. This is why over the past several years, including into Q1 of this year, approximately half of our new customers reported adopting insulin pump therapy for multiple daily injections, demonstrating that we are furthering our long-term goal to expand the insulin pump market. As we look at the broader commercial environment, the start to the year was largely consistent with what we've seen exiting 2022. While there were pressures associated with a competitor's new product launch in the United States, which created noise and delayed decision-making, the experience we've gained selling in this environment will benefit us in the back half of this year. Our sales team is excited about the increasing number of in-person diabetes education and advocacy events, and our clinical specialists are training more patients in person, which our customers report as a very positive experience. These interactions with our team contribute to overall customer satisfaction, which remains high for our technology and our services. It's why we've not seen a change in our modest attrition rate over the past few years. We monitor this in multiple ways, including through the incredible amount of therapy data regularly uploaded by our customers through our t:connect platform and renewal purchases. In fact, the number of repeat customers purchasing a new pump from Tandem once again increased meaningfully in Q1. It's also encouraging based on renewal opportunity this year is significantly higher than 2022 and continues to climb over the next few years in line with our historical pump shipments. The impact of the U.S. economic environment has also been consistent over the past several quarters. The more comprehensive payment plans now available to our customers have helped address this pressure, but it has also highlighted that there are some misconceptions held by patients and physicians about the affordability of insulin pump therapy through the DME channel. Our data shows on average, the cost for a direct Tandem customer is less than $50 monthly for our system, and nearly 1/3 pay zero out-of-pocket for the pump itself. Our commercial team is focused on driving customer awareness of these facts to counter the perception of cost as a barrier to choosing the t:slim X2 for pump therapy. Outside the United States, there isn't the same pricing sensitivity as most people are covered under government healthcare plans, where little or no additional payments are required to adopt pump therapy. Related to our international scaling activity, we continue to work through the logistics of the inventory transition to our European distribution center, which was largely done in the first quarter. We've now onboarded our distributors in France and Germany, which are two of the largest countries we serve. Once completed in the second quarter, this European distribution center will support roughly 70% of our sales outside the United States. We're already hearing positive feedback from our distribution partners that it's easing the supply chain process. We now serve approximately 25 countries worldwide, in 2023, we'll be focused on bringing the benefits to more people living with diabetes in those countries. As we have noted, most of these countries are only 10%-20% penetrated, which presents an exciting longer-term opportunity. Overall, we continue to be mindful of our competition and will capitalize on the valuable knowledge we have gained so far to inform our commercial strategy as they expand their launches worldwide. We remain excited about the t:slim X2 system we offer today, as well as the future technology right around the corner. We are starting to receive customer and healthcare provider inquiries about Mobi and there are early signs of anticipation building, reinforcing conviction in our strategy of offering a true portfolio of pumps to meet the needs of more people living with diabetes. With that, I will now turn the call over to Leigh. Thank you, Brian. As a reminder, unless otherwise noted, the financial metrics I'll be discussing today are on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release as well as on the investor center portion of our website. Worldwide sales in the first quarter were $171 million, which was in line with the high end of our expectations and excludes the deferral associated with the U.S. Tandem Choice program that launched in late 2022. Nearly half of our sales were driven by 23,000 pump shipments. There were multiple unique factors in the quarter resulting in year-over-year comparisons that are not necessarily reflective of the progress of our business, such as the impact on sales of the ongoing operational transition to our European distribution center. Beginning with our results in the U.S., total sales were $133 million. We experienced typical seasonal trends in our first quarter performance associated with insurance deductible resets. For example, the average sequential decline for pump shipments in the U.S. historically was approximately 30%. In the first quarter of 2023, the decline was 28% as we shipped 17,000 pumps. While the majority of these shipments were to new customers, renewals also provided a meaningful contribution in the quarter, with strong growth year-over-year. We maintained the improvements we saw last year in our renewal rates on an increased number of new opportunities, which underscores our high customer satisfaction. Turning to supplies, we saw an increase in both our cartridges and infusion set sales in line with growth in our in-warranty installed base to approximately 300,000 people at the end of the first quarter. Similar to pumps and our historical experience, we saw insurance-related seasonality in the first quarter impacting customer ordering patterns. Overall, our direct mix of business in the U.S., and therefore our pricing, was consistent with 2022 at approximately 35% of sales. We are reaffirming our non-GAAP sales expectations in the U.S. for the full year in the range of $650 million-$660 million based on our current referral trends for new customers and strong renewal rates. We assume that sales will increase across the quarters and that the year will be back-end loaded due to normal seasonality. When considering the sequential step-up from Q1 to Q2, historical trends show a great deal of variability. The bottom end of the range has been a low double-digit increase over Q1, which is a good starting point for how to think about this year as customers anticipate new product launches from our partners, competitors, and even our own Mobi launch. Outside the U.S., our sales in the first quarter were $38 million. We shipped approximately 6,000 pumps, bringing our estimated in-warranty customer base outside the United States to 130,000 people. This is a 30% increase in the number of our customers outside the U.S. compared with Q1 of last year. A big focus for our internal operations and supply chain team in the quarter was the continued transition to utilization of the European distribution center that Brian discussed. This is a positive move for our business, reducing logistical supply chain challenges, strengthening international distributor relations, and bringing closer correlation between our pump shipments and pump placements on patients. The first quarter impact of this transition was approximately $18 million, reflected in our pump and supply sales. Although we have substantially completed the onboarding of the participating markets, we anticipate approximately $7 million of remaining sales headwinds in the second quarter based on current distributor inventory levels. These pressures were partially offset in the first quarter by pricing benefit from the actual mix of the ordering countries. Consistent with our previously provided guidance, our full year expectations for our OUS business are in the range of $235 million-$240 million. Turning to margins, our gross margin in the first quarter was in line with our expectations at 50% of sales. Similar to our experience in recent quarters, we benefited from higher average selling prices and reduced manufacturing costs, which were offset by unfavorable product mix. While our supply gross margin modestly improved over last year, our growing install base of customers drove the proportion of lower margin supply sales higher overall. Additionally, the impact of lower sales and higher costs associated with raw materials acquired in early 2022 further pressured gross margin. Those higher material costs, combined with greater freight costs, reduced gross margin by 1 percentage point. We anticipate that these higher inventory costs will be materially behind us in the second half of this year and maintain our expectations of approximately 52% gross margin for the full year. From an operating expense perspective, we continue to diligently manage spending, prioritize investments in future growth opportunities, and pursue additional measures to create efficiencies within the organization. In relation to those efforts, we recognize the one-time $79 million charge for our in-process R&D associated with the closing of the AMF Medical acquisition, as well as $3 million in cash and non-cash severance costs in the quarter. Beyond these unique items, our increase in Q1 baseline spending compared to the fourth quarter was primarily associated with ongoing operational costs related to our recent acquisitions and Mobi development scale-up costs. When excluding the one-time transactions, as well as depreciation, amortization, and non-cash stock-based compensation, our adjusted EBITDA margin was - 12%. This was in line with our expectations, particularly in light of the sales impact of the European distribution center transition. We anticipate that our adjusted EBITDA margin will improve in the second quarter to negative mid-single digits with a return to positive margins in the second half of the year when the distribution center transition is complete. Therefore, we are maintaining our expectations for adjusted EBITDA to be in the range of 5%-6% on a full year basis. We closed the quarter with total cash and investments of $520 million. Notably, we utilized $69 million in cash for the closing of the AMF Medical acquisition in the first quarter, but remain in a strong balance sheet position. To summarize our 2023 outlook, which is provided on a non-GAAP basis, our worldwide sales are estimated to be in the range of $885 million-$900 million, including sales outside the United States of $235 million-$240 million. Our gross margin expectation is approximately 52%, and adjusted EBITDA is estimated to be in the range of 5%-6% of sales. Our non-cash P&L charges for stock compensation, depreciation, and amortization are expected to be approximately $115 million, of which $95 million is associated with stock comp and $20 million with depreciation. As a reminder, unless otherwise stated, the financial metrics I've discussed today are on a non-GAAP basis. Please refer to our earnings release in the investor center portion of our website for reconciliation to the most directly comparable GAAP financial measure. I will now turn the call back to John. Thanks, Leigh. Delivering on innovation is what drove Tandem to its leadership position in insulin therapy management. We are committed to continue doing so by serving the varying needs and preferences of people living with diabetes, the majority of whom use multiple daily injections today. This requires a true portfolio of solutions that center around simplification and delivering choice. This means choice in features, choice in device form factor, and choice in how users can wear and operate their pump. We'll continue delivering on this vision in 2023 as we plan for our upcoming new product introductions. Our goal, starting this fall, is for the t:slim X2 to be the first FDA-cleared insulin pump integrated with multiple CGM sensors. Choice of more than one CGM is not only a differentiator, it's a true realization of interoperability and opens the door for more people to adopt our technology. This empowers users to make the best sensor decision for their needs and preferences. Our t:slim X2 pump in the markets are capable of being remotely updated to integrate with Dexcom's G7 and Abbott's FreeStyle Libre sensors. These no-cost software updates will be offered to all X2 users within their warranty period. We find that launching our products in a metered fashion provides the best experience for our healthcare providers, customers, and internal teams. The key phases, including starting with internal walkabout testing, followed by scaling availability in the United States and then internationally. We've been working closely with Dexcom to finalize our Control-IQ integration with G7 and to coordinate its launch. Walkabout testing has been taking place. Launch will scale across the upcoming months, followed by our international rollout. We've also been working diligently on the integration of Abbott's FreeStyle Libre 2 and Libre 3 sensors. Walkabout testing using Libre 2 is also underway. We plan to start a scaled launch in the U.S. in the third quarter with Libre 3 as a fast follow. We believe this path will allow Libre customers to enjoy the benefits of our Control-IQ technology as we finalize the integration with Libre 3. Outside the United States, we intend to launch directly with the Libre 3 sensor as the implementation path aligns with our target launch timing. The next new technology we are preparing to launch following FDA clearance is a Tandem Mobi system. As a reminder, the Mobi pump is about half the size of the t:slim and operated by a smartphone through a mobile application. It's designed to expand our portfolio of diabetes solutions and offer people greater choice in how they wear and operate their pump. Our dialogue with the agency remains constructive as we work through the process of FDA review and responding to questions. In the meantime, we continue to prepare for its launch in the second half of the year. As you can see, we are making great progress with our future products in addition to the strength that we offer in our t:slim X2 today. We have historically introduced new diabetes technologies at an industry-leading pace, so it's particularly noteworthy that we will be bringing multiple new products to market in the coming months. Our employees are extraordinary, and I'd like to express our thanks to everyone for your efforts in making both Tandem and our technology offerings positively different. We remain confident in our ability to achieve our goals for the year, which focuses on successfully executing our business plan, supporting our customers, and building shareholder value. With that, I'd like to ask the operator to open the call up for questions. As a reminder, to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. Our first question is from Matt Miksic with Barclays. Your line is open. Hi. Thanks for taking the question. Congrats on a really solid quarter here. Maybe John, if you could describe the walkabout process, and the sort of the ramp-up of the integrations that you talked about, a little bit different than the sort of clearance and launch cadence that we're used to. I just have one follow-up. Sure. Well, the sequence of releases is really going to follow the sequence of the FDA approvals for both Dexcom and Abbott. Dexcom will be first, and then that'll be followed by Abbott. As I said in the prepared remarks, we conduct this walkabout testing really to help us understand and optimize system performance and customer experience. It's followed by a scaled launch, which is going to happen in the upcoming months, and we would expect to see a meaningful number of customers using the t:slim G7 in the third quarter. I think that when it comes to the international launch, it'll follow the U.S. launch. It'll occur on a country-by-country basis for G7, and it'll commence in a relatively short timeframe after the U.S. launch starts. When it comes to the Abbott product, we are also in the walkabout testing phase right now, and that scaled launch process is gonna be delayed a little bit compared to Dexcom. It'll happen in the third quarter. I think that, you know, it'll happen in the third quarter. We would see meaningful numbers of people using the system as we enter the fourth quarter. That's great. Thanks so much for the color. One follow-up, if I could, John. We talked about this process, and we pick up on this a little bit when we talk to clinicians, and how they're seeing patient choice kind of center new patients considering, you know, the two leading closed loop systems out there in the market. It seems to have kind of stabilized in sort of a 60%-70% of new patients maybe flowing to the other system in the very anecdotal checks that we've performed. What's your sense? I mean, is it sort of crested? Is it stable? You know, is there anything else coming up in the narrative and dialogue that clinicians are having with patients that gives us a sense of, you know, what that environment's like at the moment? Yeah. Matt, I think you're right. I think we sort of see the situation as having stabilized. There still is pressure, for sure, but it's not any better and it's not any worse than it has been entering this year. I think we probably expect to see the pressure for another quarter or two until we start to see the benefits of these new technologies, new waves of innovation come to market in the second half. We would agree with your characterizations. One moment for our next question. Our next question is from Steven Lichtman with Oppenheimer. Your line is open. Thank you. Evening, everyone. Just one question and then just one quick clarification just on terms of making, it looks like you're making nice progress on the integration with the CGM. That is not embedded in guidance, right? Any sort of contribution you'd get in the latter part of the year. That's just clarification. Just going back, Brian, to some of your comments about some of the experiences you've learned in terms of competing, you know, with the newer products on the market, and that could help you in the back half of the year. Can you talk a little bit more about what that means? You know, I think you had talked a little bit about the pricing dynamics and some clarifications there. You know, if you can clarify what you mean by that and what you'll be putting in place. Thanks. Sure. Leigh, you want to catch the first one? I'll start with just Sure. I'll start by confirming that we do not have any new product contribution in the guidance for this year. To my piece, I commented earlier that first quarter was a lot like fourth quarter. The environment's pretty stable right now from a COVID perspective. We're not seeing those challenges, maybe a few staffing challenges. Now we sit with some of the economic pressures, and I think we've addressed those very well. Obviously the competitive piece, you know, as part of the prepared remarks is something that we see. I would say most of our conversations with our healthcare providers start with the strength of Control-IQ and the support that they get from the Tandem team. We take a look at that six or nine-month window now that the competitive product has been available on the market. Those patients are coming back to the endocrinologist with feedback, and we can see how they're doing. The physicians can see how they're doing. Again, it highlights the strengths of our product and to some extent, you know, the strength of their products. We feel very good about our offering and, you know, continue to lean into the size, the touch screen, the ability to disconnect, you know, all the features that folks have liked. Our team has done a tremendous job there. You know, anytime there's a product introduction like that, it takes a little while to kind of play out and that pent-up demand and early excitement. I think we're moving into a more stable environment now going into Q2 and the rest of the year. Great. Thanks. Appreciate it. Thanks, Steve. One moment for our next question. Our next question is from Chris Pasquale with Nephron Research. Your line is open. Yeah, thanks. John, one question on Mobi and then, and one just on the model. Are you expecting any slowdown in pump shipments as Mobi gets closer to the finish line? You talked about anticipation starting to build. We have seen in the past when you guys have launched new products, a bit of an air pocket in front of that. Is that contemplated in your outlook for the year? I'll take that one, Chris. Yes, anytime a new product is introduced into the market, whether it's a competitive product or our own product, we tend to see noise in advance of it. It's usually the strongest in the time from when FDA approval is clear, comes around that timeframe, up until the point where it's actually released on the market. When we look at the cadence of how sales will spread across the year, we're taking that into consideration, which is part of the reason when we talk about the sequential step-up into Q2, when we think that noise might begin, we're cautioning you to start on the end of the low double-digit step-up, which is the low end of the range that we've seen historically. Okay, that's helpful. Just looking at the international pump revenue this quarter, there was a pretty big delta between pumps shipped and the revenue you guys recognized there seemed to imply a step-up in ASP. Is that just because of mix, or is another dynamic happening there related to the distribution center? You know, it actually is related to the distribution center, but it is a price benefit. If you think about the sales headwind that we saw was when within particular countries. It was a different mix of ordering countries within the quarter than what we would see on a normalized basis, which gave us that price benefit this quarter. It's not something, though, that I would model in or expect to continue for the future. Okay, thank you. Thank you. One moment for our next question. Our next question comes from Brooks O'Neil with Lake Street Capital Markets. Your line is open. Good afternoon. The last few product innovations you guys have delivered have largely been delivered through the free software download. I know we're anticipating that for the integration with G7 and Libre products. How do you view the impact to your revenue line from those free software downloads versus the impact you might anticipate from Mobi, which is a complete new form factor? I'm gonna say that... Oh, hi, Brooks. First of all, how you doing? I'm doing well. I would say that, Good. We expect to see, you know, favorable revenue impact from the G7 launch. It's a brand new form factor. It's got a faster startup time. I've talked to people who are using it really is, people really do like it. We think that it's gonna be a positive impact, as Leigh mentioned. We also think that it could help us with renewals to have people renew sooner. That's all good. I think that, you know, Abbott, when you think about Abbott, there's a quite a large number of people with Type 1 that are using the Abbott sensors that are not using pump therapy today. That may, you know, represent an even a bigger opportunity than what we see with. The Dexcom. I do think that when we bring Mobi to market, it's a brand-new form factor. It's going to be controlled by the mobile app. It's got, you know, the discretion and the ease of use, you know, just the simplicity of interacting with a system, that's on a mobile app. We think that's gonna have a positive effect on sales. I think that, you know, all three of them are gonna have a positive effect, and I think that, you know, probably, you know, we'll see some effect in the latter part of this year. The good news about 2024 is we get the full benefit of these products, including Tandem Source, which we haven't talked much about, through the entire year of 2024. Great. Thank you very much. Thank you. One moment for our next question. Our next question is from Larry Biegelsen with Wells Fargo. Your line is open. Hi, this is Nathan Treybeck calling for Larry. Can you talk about how new starts trended in Q1 relative to renewals and the underlying drivers? I guess what you're seeing in April so far? Thanks. Sure. The way this quarter shaped up, you know, as John and Brian both said, it was pretty stable, I would say, and consistent with the type of environment we were seeing in the fourth quarter. As we came into the year, we anticipated that overall pump shipments in the U.S. would follow typical sequential trends, which is a decline of about 30%. In this quarter, indeed, the decline was about 28% for new and renewal. Renewal pumps are continuing to grow to be a bigger piece of the pumps that we ship, but new pump starts are actually still the majority there. I would say the dynamics are the same in that we've seen consistent strong renewals, even in the light of this environment. New pumpers are where we have seen the pressure. You know, as we've talked about, we still firmly believe we have the best product out there, and we continue to fight for that new market share. Great. If I could just follow up. In terms of new competition, your competitor recently got approval for their 780G pump in the U.S. How are you thinking about the competitive landscape once this is on the market? Thanks. Well, you know, we've been competing against that product now in OUS countries for many quarters. You know, while we know that once, you know, the product does come to market, as I said, sometime this summer, we expect them to step up promotion. You know, we think we have a better product. We think we have the confidence and trust of the endo community in the States. When you look at the new device, it's certainly a better device, but it's still the same form factor, and it has a sensor that requires finger sticks. You know, while there's new competitive products on the market, first of all, it's not a surprise. We've been expecting this for a while, and it hasn't changed our conviction. We remain confident in our ability to hit our goals for the year, even with this coming to market, mid-year. Thank you. One moment for our next question. Our next question comes from Danielle Antalffy with UBS. Your line is open. Hey, good afternoon, everyone. Thanks so much for taking the question. I just have two questions, if I could. One on the competitive environment, and that's really around what's factored in. I mean, I think we were all a little surprised about the recent product approval from one of the major competitors. What's factored in to the guide there? Then, my second question, I'll just ask it now. John, you did touch on this a little bit, but just trying to think about the opportunity that exists here with Libre integration, given the size of their installed base. Obviously it's a smaller installed base, or they have less market share, I should say, in type one. Is this something that you think could be an inflection driver and sort of change the tide here back to accelerating growth? Or is this more muted? I mean, how should we be thinking about this? I appreciate it's not in 23 numbers, but, you know, as we look at 24, et cetera. Thanks so much. Sure. Thanks for the questions, Danielle. I'll take the first one about what's factored into guidance in relation to the competitive environment. We do always, when a new product is being introduced, factor in that there will be noise in the market. In fact, we have been anticipating, I guess you would say, the approval of this product now for a year or two. It's something that we've always assumed could be just right around the corner. Now we have more certainty about the timing. As we look into Q2, we think it'll be noisy. Which is why when we look at our historical range of, how Q1 usually transitions into Q2, we expect to be on the low end of that, in the low double digits in terms of sequential growth, with that kind of noise that's coming in the market. Also add to it that there's going to be conversations, people who might be waiting for G7 to be available on the, on the pump, as well as people starting to talk about Mobi. You know, that's what we've thought about from a competitive perspective and the noise that could come this year. Danielle, regarding Libre, I think the first thing to say that's important is that, you know, we're all about providing choice, and we, you know, we are not engaged in any of the competitive sort of competition between the sensor companies. All we're trying to do is provide a device that has choice of sensors so that, you know, people who have a natural tendency to choose Dexcom can, and if they have an interest in Abbott, they can do that also. That being said, I, you know, as we understand it, there's approximately 300,000 people who have Type 1 in the U.S. that use the Abbott sensor. Certainly that becomes an opportunity for us to, you know, take advantage of that community. you know, if we even get 30% or 35% penetration with that community, there's, you know, it's 100,000 people that are potential, you know, candidates for pump therapy. I think that there is a big opportunity with the Abbott device, and I think it's also larger outside the United States. You know, we look at it as a growth driver that's going to, you know, it's really an important growth driver that allows us to get to the numbers we've talked about in the 2027 timeframe. It's a, it's an important part of our, our pipeline going forward. Thank you. One moment for our next question. Our next question comes from Matt Taylor with Jefferies. Your line is open. Hi, thanks for taking the question. Hey, John and Leigh. I just wanted to follow up on that line of thinking about the Abbott opportunity. John, you've mentioned 30%-35%. Have you done market research on the percentage of people that could convert? Or how do you think about the opportunity overall for them to convert to MDIs since they haven't done that, you know, previously, and your opportunity within that? Yeah. As I said, I think that there's about 300,000, and if you look at the current penetration rate of pump therapy in the U.S., it's about 35%. In my mind, that kind of defines a starting point. We certainly are gonna have to sell to them, help convince them of the benefits of pump therapy and, you know, just work the process. I think that when we set a goal for ourselves, I think that's a reasonable starting point. I think as they become more and more familiar with the benefits of pump therapy connected up to a sensor that they're comfortable with, we think that represents a significant opportunity for growth in the upcoming couple of years. Maybe just one follow-up. I mean, that makes sense. Could you help us think about the timeframe that you would expect some of those folks to convert, and what are the key factors in whether they're gonna convert in, you know, quarter one or quarter six after the integration? I think that the, you know, I think it's not gonna be overnight for sure. I think that there's definitely going to be a selling process, a co-promotion, co-marketing process that's going to have to happen. I think that, you know, it does represent a large opportunity for us, and I think it's something that our sales force is excited to get involved in. Great. Thank you. One moment for our next question. Our next question comes from Matthew O'Brien with Piper Sandler. Your line is open. Thanks for taking my question. This one's for Leigh, and I guess it does have two parts, so it's not a singular question. Leigh, is there any demonstrable change as far as, you know, MDI patients or competitive conversions you wanted to call out in the quarter? More importantly, as I look at the model here, and you guys are sticking with the U.S. number for the full year, and based on your commentary, which I think you said low double digits off of what you just put up in the U.S. When I do that math, I'm getting like 42% of the full year number is what you should generate in the first half. Historically, it's been, you know, last year it was 47, the year before that it was 44. It's just a big ramp in the back half of the year with a competitor making more noise in the space, not including Mobi, et cetera. I mean, you know, why are you confident in being able to get back to, you know, get up to 650, even at the low end of the range? I mean, can you really walk us through how you get there? Sure. Thanks for the questions, Matt. I'll start with the first one and how new pumpers broke down. It again remained consistent at that 50/50 mix of about 50% coming from MDI and 50% from competitive conversions. No change in those dynamics there today. Again, just to remark that renewals are becoming a much bigger contribution to our pump shipments every quarter. That leads to the second part of your question about the U.S. this year and why we're so confident in the back half. First, I would say 2022 probably isn't a good comp for how the first half and second half split, just based on the dynamics across the year with a much healthier environment in the first half than it was in the second half. A 40-60 split isn't too unusual for what we've seen in our history. This year, the conviction comes from the fact that partially, more of our business is coming from recurring revenue streams. More like 60% this year, which is higher than what we've seen in the past when you factor in the supply sales stream that we see from our large install base, as well as renewals growing pretty significantly. If we look four years ago, there were about 50,000 people that bought Tandem pumps in the U.S., up from 30,000 the year before, and those have a strong seasonal scale to them. When you just think about normal seasonality, you think about the predictability of renewals coming and the predictability of supplies, you know, it seems pretty normal for us to be able to achieve that kind of year, and we have a high level of conviction in doing that. Got it. Thank you. One moment for our next question. Our next question comes from Jayson Bedford with Raymond James. Your line is open. Good afternoon. Just maybe a couple questions. They're probably more, excuse me, geared to Leigh. On international, the historical kind of sequential dynamics are kind of all over the place. You called out the $7 million expected impact from the distributor dynamic this year in 2Q. Any direction you can give us on international revenue in 2Q? I think, Jayson, the way to look at it is we gave a headwind that hit us in the fourth quarter of about $6 million. It was about $18 million in Q1. When you add those back, I mean, considering there's still a little bit of variability in there because we haven't fully transitioned, that gets you to almost what I would call a normalized run rate type of number. You can use that to think about what to build off of as you look forward for our OUS business. We're still very excited about the opportunities there, with, you know, we have new product introductions that come outside the U.S., and there's a lot of excitement about Control-IQ. There's still great growth opportunity there. It's just we need to work through these headwinds here in the near term. Okay. Just the up low double-digit, comment that you've made here, that was related to the U.S. business, right? Yes, thanks for asking that for clarification. It's U.S. pump shipments is what I'm really referring to. We look at our traditional seasonal patterns there, that seems like a good place to think about the starting point for Q2 of this year. Okay. Okay. Just to true-up kind of the apples to apples comparison here, appreciate the 430,000 in warranty user comment. What was the in-warranty install base exiting 22? Just so I make sure we're comparing the install base on an apples to apples basis. Sure. It was off the top, I think it was about $420,000. There's one thing I'd like to point out there. I think it's a question I've gotten a number of times, is how to translate that installed base number into what is an ordering base number and/or how to view attrition. That install base number that we provide is intended to be representative of who is in warranty in any given period. While I think it's a good directional tool for modeling supplies, for looking at renewal opportunities, it's not the way to measure attrition because it's straight math. As you add new people into the warranty base and you drop off people whose warranties have expired, that's not how the ordering patterns work. We have people who have stopped using the pump in warranty. We have many people who use the pump out of warranty. It's not necessarily a way to think about attrition, but it is good directionally for modeling, like I said, supplies and thinking about renewal opportunities. Your comment is you don't believe attrition- Jayson, I'm gonna need to ask you to jump back into queue. Yeah. Sorry. That's okay. Thanks. One moment for our next question. As a reminder, please limit yourself to one question and one follow-up. Our next question comes from Joanne Wuensch with Citi. Your line is open. Good evening. I'm just wrapping my head around t:slim X2. Is the only thing different between that and the previous t:slim, the addition of G7 and Libre 3? Part of that is, you'll be going to market with Mobi as well as t:slim X2. How does your sales force sort of decide which one it's selling on which day? Thank you. Joanne, I just wanna be sure I understand. Right now, we have t:slim X2 on the market, and we are going to add the capability for G7 and FreeStyle Libre 2 and 3 to t:slim X2. We will be providing a software update to the current install base so that they can actually update and use these new sensors as they come to market. We are also working on the t:slim X3, which is a technology upgrade to t:slim X2, and that's something that's going to be coming out here in the near future. It's essentially just to make sure that we just preserve the life of the t:slim product 'cause it's been on the market for about 10 years right now. There's a number of technology upgrades that'll enhance the capability, microprocessing thing, skills, and think there's capabilities as well. I just wanna be sure I understand the question when you're asking. I'm not sure if I did. Yes, you did. I probably didn't say it as clearly as you answered it. T:slim X3 is coming out at the end of this year also? I'm just trying to get my head around how many new things you're talking about in the second half of the year. Well, right now, we have four new products. We have Tandem Source, which is something we really haven't talked about that much, and that's coming out here in the relatively near future. As we talked about the two sensor integrations, you know, we expect to start scaling launch here in the near future with G7, and we'll start the scaling launch of that in the third quarter. Then we're waiting for approval on Mobi. So there's really four products that we're looking at happening here in the third and fourth quarter of this year. T:slim X3 is out in time. It'll be the next product that we haven't been specific about when it's going to be available to the marketplace. It's out there probably 12-18 months from now. Terrific. Thank you so much. You're welcome. One moment for our next question. Our next question comes from Mathew Blackman with Stifel. Your line is open. Good afternoon, everybody. Thanks for taking my question. I've got one clarification question for Leigh and then a bigger question. Maybe Leigh, just to start, I'm not sure if we're doing the math right, and you gave us some different metrics to play with this time. On renewals, was the 1Q number something approaching 5,000 pumps, something in that neighborhood? Just any help there. Then I guess I'll throw the follow-up question, and this is probably for John and or Brian. I was hoping you'd give us some sense of your strategy in the primary care channel. There's obviously still some opportunity in endo offices, but, you know, it seemed to be a large still untapped cohort of type ones and type two intensives that use PCPs. I know today you target high prescribing insulin docs, and that captures some of the opportunity. Do you need to go deeper and broader than that? If so, what could that look like? Frankly, why wouldn't that be an initiative that you'd be starting now, if you aren't already? Thanks. There's a lot in there. I apologize. Yeah. I'll give you a quick response to the renewals question. The, the information that we've shared is that renewals continue to be strong. What's important to note is that the rates at which we convert customers when their warranties expire was consistent again this quarter with last year, even first quarter. Comparing a healthier environment to what we're seeing today, which is a little bit more challenged, it says a lot about our own customers and how they really want to... They really wanna stick with the product. They love the product, they love our customer service and everything that we offer. In terms of the number, you know, another piece of information that might be useful, I mentioned the sequential decline for pump shipments from the fourth quarter to the first quarter. It was approximately the same for both the renewal population and the new population. Renewals are becoming a bigger% of what we ship each quarter, and we expect that to continue throughout the year as the number of opportunities grow. But new pumpers will still be the majority. Hopefully that's a little bit of information to help you understand the renewals trajectory. Brian, why don't you take the question on the primary care physicians? Yeah. We definitely do see primary care physicians where there is a desire to interact with a pump company like Tandem. I would say all of our territories have a certain percentage of PCPs that they do call on. We work very closely with our CGM partners as well, who have, you know, moved into that space more aggressively. When they start to get inquiries about pump therapy or the opportunity to work with their patients, they pull us into several of those meetings. You know, as physicians become more comfortable with that, we certainly will spend time with anyone who's interested in learning more about pump therapy, expanding to their patients, and quite frankly, getting trained on it and support them just like we would in endocrinology office. Clearly the majority of our time is spent in our big diabetes education centers, where we see the type ones predominantly sitting. As we start to look at type two more aggressively in the future with Control-IQ and our future products, that becomes probably a bigger piece of our strategy to grow in the primary care space. All right. Thank you. Yep. One moment for our next question. Our next question comes from Joshua Jennings with TD Cowen. Your line is open. Hi. Good afternoon. Thanks for taking the questions. Wanted to ask about the cost per month for patient for pumps of less than $50. Does that include the expenses related to CGM and the accessories like infusion sets within the DME channel? Can patients access infusion sets and reservoir and CGMs using their pharmacy benefit and pair them with a pump, Tandem pump, t:slim X2 through the DME channel? I have one follow-up. I'll take that one. All right. Yeah. The infusion sets cartridges are only available through the DME channel today. That $50 or less per month does not factor in the CGM portion of, you know, of their therapy. It's just strictly the, you know, pump. It's spread out over time as well as the infusion sets and cartridges necessary to operate the system. Can Tandem patients access their CGM through their pharmacy benefit instead of the DME to cut down on costs for the CGM? Absolutely. They have a choice if they wanna get it in conjunction with their pump supplies or they can separate, you know, separate those two and get those through the pharmacy channel if their benefits allow it and it works for them. There's no hesitation to do that if available for them. Just on checking with endocrinologists and, you know, the very positive feedback, clearly, as you're well aware of on the Control-IQ algorithm. You know, sometimes we get feedback on just, you know, cross-trial comparisons being challenging. My question is, one, just can you just remind us of the roadmap of enhancing the Control-IQ algo? How are you thinking about investing in a head-to-head trial against your competition? Would that be worthwhile to kind of formally put the stake in the ground that the Control-IQ algo was the premier solution? Thanks a lot. We are and have been since 2015, significantly expanding our internal capabilities to develop algorithms. We have been working on it since that time. 2015 was when we first established the relationship with TypeZero, and I think that we established that relationship because we didn't have the capabilities initially. Certainly we have been since then, and we continue to work with a number of universities and other institutions to just improve the knowledge and, you know, to run clinical studies and just get better feedback on the performance and ideas on where we ought to be heading. I will say that, as you know, we have our second clinical study underway right now to evaluate certain features for Control-IQ. We would, you know, we expect that that's going to inform a pivotal study that would be run sometime next year. That study would be what would be required to get clinical approval for that next generation system. I think some of the key features that we've talked about in the past have just been simplification of the bolus workflow, personalization, and then there's a number of things that I think we can do to just improve the overall experience and potentially make the algorithm more aggressive. That's what we're working on right now, and I think that as we get closer to defining the pivotal study, we'll talk more about what the specifics are. In addition to that, we are working on, I will call it Control-IQ 1.5. This is just an algorithm that's going to enable a broader cross-section of people with big, larger body mass and also younger children that have smaller body masses to use the system. There'll be a few features that are going to be available in that. That'll be available in a relatively short period of time, probably sometime next year. You know, most of the work that we're focused on right now is really on Control-IQ 2.0. We're also looking beyond that. I mean, certainly we are working towards ultimately getting a fully closed loop system, but that's gonna be out in time. Great. Thanks. Any impetus to hold support or invest in the head-to-head trial with competitive technologies? You know, I think, Joshua, right now there's just a lot of clinical data out there. I think we feel like clinical data stands for itself and it's strong. I think we compete quite well, both from the, you know, the sort of the clinical information as well as the real world data. At this point in time, I don't think we see the need to do that. I think that when you talk to people about it, they certainly agree with us that our device is the best on the market. Understood. No, thanks a lot, John. You're welcome. Take care. One moment for our next question. Our next question comes from Travis Steed with Bank of America Securities. Your line is open. Hi, this is Stephanie Piazzola on for Travis. Thanks for taking the question. Heard the clarification on the U.S. pump shipments up low double digits next quarter, but wanted to see how we should think about overall Q2 revenue on a sequential basis. The Street is at $215 million, so wanted to see if you had any thoughts there. On the Q2 EBITDA margin guide of negative mid-single digits, previously it seemed like it would be flat in Q2, so I was wondering if that's gotten worse versus before, and if so, why? Thanks for the question, Stephanie. Starting with sales worldwide in Q2, I think it was very important to get the information about where we think US pump shipments trend, because that's one of the biggest drivers, which is, I would expect, a softer expectation than what people have right now. It's really in anticipation that the market could be noisy in Q2, but we think it's temporary. It's really just ahead of some really exciting products that are around the corner for us, and until the newest competitive product starts coming out to market, which we feel will compete effectively against. The other piece that I think is really important to understand about the expectations for Q2 is how the distribution center transition outside the US is impacting the year. Originally, I had given the guidance that it's $25 million for the year and only said heavily in the first quarter. Now I think, it's important to take note that that $7 million will be a headwind in the second quarter, which I think also will soften expectations from where they are today. You know, I think we want to be cautious as we step into Q2 and the environment that we're in, but we feel like everything that we're talking about, they're all just temporary items, and we feel convicted that we can achieve the second half, you know, as after what we see in the second quarter. To your question about the EBITDA, a lot of that is just translating what's happening from the OUS market. As you think about the sales trajectory, we're closely managing costs. It's really the sales that are influencing what EBITDA looks like, what it looked like in the first quarter and what we expect it to look like in the second quarter. Once we get past that transition, you know, EBITDA should start to track more closely to pump sales across the year. We do fully expect to be back to positive in the third quarter and for the back half of the year. One moment for our next question. Our next question comes from Alex Nowak with Craig-Hallum. Your line is open. Okay, great. Good afternoon, everyone. What is just the latest on the back and forth with the FDA and the Mobi submission? Has there been any questions that have been raised? Kind of stopped the 510(k) clock? Have you moved into labeling discussions? Just where does that stand? You know, we're having a constructive dialogue with them right now. It's, you know, I would say that there's, you know, We're at a point where we're responding to questions, and we're actually in the process of answering some questions, which in some cases take time because there might be additional testing and things like that that's going on. I would say it's constructive, and I think that, you know, it's basically encouraging that we see a lot more activity from the FDA in the last couple of quarters. You know, As we've said in the past, though, it's difficult to predict exactly when we would expect to get approval. You know, the organization is preparing that's going to happen in the second half of this year, and it'll take us roughly a quarter to have the device on the market from the time we actually receive the clearance. Okay, that makes sense. Then in the past, you've talked about on the operating cost base that. Well, I guess if you look at the operating cost base, you have doubled that size of the expense lines, versus 2021, but the revenues hasn't doubled. I know a lot has been happening the last two years, but you're also getting ready for a lot of new product enhancements coming. I mean, how should we start thinking about efficiencies and margins over the next couple quarters, next year or so when these new products come online? Should a lot of that start to drop to the bottom line? Just help me get back to this free cash flow positive territory that we're pretty close at, but now we're a little bit farther away. I'll start just the first half of this year is inordinately pressured by this transition that we're seeing outside the U.S. That's one of the biggest pressure points that's preventing us from being positive on an EBITDA line for this past quarter and this upcoming quarter. What it takes is we're prudently managing our spending. We're looking very closely at where we're putting our dollars, where are the right places to make investments, and more importantly, can we find the efficiencies not only for right now but for the longer term. We continue to focus closely on a lot of our customers, facing services that we offer, moving to more automated or digital solutions. That's where Tandem Source as a new product will really come into play. Not only will be very helpful from the physician perspective and the efficiency it can create in their practices, but also internally and how we can offer patients something that's more like a retail experience as opposed to a lot of the today what's a required human interaction. As we look forward, that's one of our biggest opportunities for the longer term to create efficiencies within the operating expense line to help us drive those margins up. We still remain confident that we can achieve our long-term objectives there. We have our final question comes from Mike Polark with Wolfe Research. Your line is open. Hey, good afternoon. Thank you for taking the questions. I have a question about this kind of emerging bring your own sensor paradigm. Do you have any early flavor for whether Control-IQ algorithm performs similarly with the Dexcom products as Libre, or are you sorting that out now? And kind of if you could speculate, what's the future state of this? Are the pumps and sensors indifferent, or might there be some quality and performance variances that we eventually know about in one, two, three years? You know, I think that we've carefully evaluated the Abbott sensor, and I think we feel very confident that it will perform very well with Control-IQ. We plan on using the sensor data as soon as we initiate the sensor session to power the system and to actually inform Control-IQ. You know, we have confidence that the system is going to work well. You know, I think it just comes down to personal preferences. I mean, some people prefer one sensor over the other. You know, I think that it just gives people choice. I mean, what's going to happen is it'll simply just be a touch screen on the system, and you'll be able to choose whichever sensor you prefer. And I think that's the idea here is just to give people choice. Thank you. A boring follow-up. The reporting change, supplies now instead of infusion sets and cartridges, is that permanent? Will there be a breakout in some other materials? If not, why the change? Sure. You're right, we did make that change this quarter. Frankly, the relationship between cartridges and infusion sets has been so consistent that it seemed like an unnecessary level of detail. The way it has been tracking, you can usually see that infusion set sales run about two to two and a half times cartridge sales. It really just follows the use pattern of the patient. There's not a lot of variation there. Thank you. You're welcome. This concludes today's conference call. Thank you for participating. You may now disconnect.